Phase I Human Analytics (HALO) Study

Clinicaltrials.gov ID: NCT05423860
db-list-check Status RECRUITING
b-loader Phase
b-people Age 45 - 90 Years
b-bullseye-arrow Enrollments 2000

Conditions

Cardiovascular Diseases, Cancer, Dementia, Traumatic Brain Injury

Summary

Discover, optimize, standardize, and validate clinical-trial measures and biomarkers used to diagnose and differentiate cardiovascular, oncologic, neurologic, and other diseases and disorders. Specifically, our research study endeavors to improve disease and disorder diagnosis to the earliest clinical states, in preclinical states, and to develop ensemble multivariate biomarker risk scores leading to cardiovascular, oncologic, neurologic, and other diseases and disorders.Additionally, the study aims to:* Evaluate data analysis techniques to improve diagnostic accuracy and reduce time to diagnosis. * Evaluate data analysis techniques to improve risk stratification for participants through machine learning algorithms. * Direct participants to relevant and applicable clinical trials.

Detailed Description

Electronic medical records contain data that may indicate increased risk for certain diseases and disorders, but clinicians cannot easily discern the subtle patterns required to change their diagnostic and treatment patterns. This study seeks to use machine learning and data analysis techniques to increase diagnostic confidence and reduce time-to-diagnosis related to cardiovascular, oncologic, neurologic, and other diseases and disorders.

The study endeavors to develop ensemble multivariate biomarker risk scores to predict future development of diseases and disorders, improve diagnosis in preclinical states and increase diagnostic accuracy in the earliest clinical states. We also aim to evaluate data analysis techniques to improve diagnostic accuracy and reduce time to diagnosis, improve risk stratification for participants through machine learning algorithms and direct participants to relevant and applicable clinical trials upon physician review, approval and recommendation.

Locations

1 location Found with status Recruiting

Status

  • RECRUITING

Contact Person

  • Bernadette M. Greenwood, MSc
  • 760-766-2047

Principal Investigator

  • Christopher R. Hancock, MD

Eligibility Criteria

Inclusion Criteria:

Treatment Naïve patients:

* Male, 45 years of age or older.
* Diagnosis of prostate adenocarcinoma.
* Clinical stage T1c or T2a.
* Gleason score of 7 (3+4 or 4+3) or less.
* Three or fewer biopsy cores with prostate cancer.
* PSA density not exceeding 0.375.
* One, two, or three tumor suspicious regions identified on multiparametric MRI.
* Negative radiographic indication of extra-capsular extent.
* Karnofsky performance status of at least 70.
* Estimated survival of 5 years or greater, as determined by treating physician.
* Tolerance for anesthesia/sedation.
* Ability to give informed consent.
* At least 6 weeks since any previous prostate biopsy.
* MR-guided biopsy confirmation of one or more MRI-visible prostate lesion(s) with Gleason score of 7 (3+4 or 4+3) or less.

Salvage candidates will be accepted upon physician referral.

Exclusion Criteria:

* Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI.
* Severe lower urinary tract symptoms as measured by an International Prostate Symptom Score (IPSS) of 20 or greater
* History of other primary non-skin malignancy within previous three years.
* Diabetes
* Smoker

Study Plan

dementia

Patients with a diagnosis of dementia

  • OTHER:

    no interventions will be performed (observational)

    Description:

    Not applicable. (no interventions will be performed with this observational study

Prostate cancer

patients with a diagnosis of prostate cancer

  • OTHER:

    no interventions will be performed (observational)

    Description:

    Not applicable. (no interventions will be performed with this observational study

breast cancer

Patients with a diagnosis of breast cancer

  • OTHER:

    no interventions will be performed (observational)

    Description:

    Not applicable. (no interventions will be performed with this observational study

Normal

Patients without a diagnosis

  • OTHER:

    no interventions will be performed (observational)

    Description:

    Not applicable. (no interventions will be performed with this observational study

tramatic brain injury

patients with a diagnosis of traumatic brain injury

  • OTHER:

    no interventions will be performed (observational)

    Description:

    Not applicable. (no interventions will be performed with this observational study

Outcome Measures

Primary Outcome Measures

Prostate cancer Gleason score

Time Frame: Up to 5 years after treatment

Prostate cancer ISUP grade group

Time Frame: Up to 5 years after treatment

Prostate cancer staging parameters

Time Frame: Up to 5 years after treatment

Prostate cancer specific mortality

Time Frame: Up to 5 years

Secondary Outcome Measures

Lower urinary tract symptoms (LUTS)

Time Frame: Up to 5 years after treatment

Erectile function

Time Frame: Up to 5 years after treatment

Emotional well-being

Time Frame: Up to 5 years after treatment

Incontinence level

Time Frame: Up to 5 years after treatment

PI-RADS category

Time Frame: Up to 5 years after treatment

Timeline

  • Last Updated
    October 14, 2022
  • Start Date
    June 21, 2022
  • Today
    February 5, 2025
  • Completion Date ( Estimated )
    March 1, 2037

Similar Trials

light-list-check RECRUITING light-blue-people 21 - 64 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people ≥ 65 Years